文献速递多重用药衰弱、肌少症与跌倒

多重用药与临床相关肌少症风险:柏林老龄化研究II结果

Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2017-01-01

多变量校正性别、年龄、共病和体力活动后,多重用药仍与肌少症风险显著升高相关(OR=2.24,95%CI 1.33-3.75)。

要点

  • 多重用药(≥5种药物)与临床相关肌少症风险独立相关,OR=2.24。
  • 多重用药者肌少症比例16.3%,非多重用药者6.9%。
  • 多重用药还与步速下降和疲乏比例升高相关。

核心结论

  • 多重用药与以低ALM/BMI定义的临床相关肌少症存在关联,校正共病和体力活动后关联仍显著。

主要发现

  • 多重用药者肌少症比例高于非多重用药者(16.3% vs 6.9%,p<0.001)。
  • 多重用药者BMI更高(p<0.001)、ALM/BMI更低(p<0.001),但平均ALM无显著差异。
  • 多重用药还与步速下降和疲乏比例升高相关。
  • 多变量校正性别、年龄、共病和体力活动后,多重用药与肌少症风险升高相关(OR=2.24,95%CI 1.33-3.75)。

关键数值与推荐

  • 多重用药定义为同时使用5种及以上药物(处方和非处方)。
  • 肌少症定义为低ALM/BMI比值,采用经验证的分性别切点。

临床怎么用

  • 对多重用药的老年患者应关注肌少症风险,可将用药核查与肌少症筛查结合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia affects more than 10% of older adults. Next to age-associated physiologic changes, diseases like diabetes or inflammatory, neurological, malignant and endocrine disorders may contribute to the development of sarcopenia. Likewise, polypharmacy, i.e., multiple drug use, is common among older adults. Although the two conditions frequently co-occur, the association of polypharmacy with sarcopenia has not yet been examined. We investigated the association of polypharmacy and sarcopenia in a large cohort of community-dwelling older adults (60-84 years). METHODS: Thousand five hundred and two participants from the Berlin Aging Study II were included. Polypharmacy was defined as concurrent use of 5 or more drugs (prescription and nonprescription). Body composition was assessed with dual-energy X-ray absorptiometry, and appendicular lean mass (ALM) was calculated as sum of the four limbs' lean mass. Sarcopenia was defined as low ALM-to-body mass index (BMI)-ratio using validated sex-specific cutoffs. RESULTS: Mean age was 68.7 ± 3.7 years, 50.7% were female. The median (interquartile range) number of drugs was 2 (1-4); 21.1% of subjects reported regular use of ≥5 drugs. Subjects with polypharmacy were more often sarcopenic according to the applied ALM/BMI-cutoffs (16.3% vs 6.9%, p < 0.001), with a higher BMI (p < 0.001) and lower ALM/BMI (p < 0.001), but no significant difference in mean ALM. Notably, polypharmacy was also associated with higher rates of reduced gait speed and exhaustion. Even after multivariable adjustment (sex, age, comorbid conditions and physical activity) polypharmacy was consistently associated with a significantly increased likelihood of sarcopenia (odds ratio = 2.24, 95% confidence interval [CI] = 1.33-3.75). CONCLUSION: Polypharmacy is associated with clinically relevant sarcopenia, as assessed by a low ALM/BMI.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. König M, Spira D, Demuth I, et al. Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28481965. doi:10.1093/gerona/glx074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。